drugset / Trial / NCT02172781

Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

NCT02172781

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

Timeline

Start
2001-01
Primary completion
2001-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule 0.5 mg Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled

Indications

No indication recorded.